Cartesian Therapeutics, Inc. (RNAC) - Dilution Analysis

10-Q filing | 26.9M shares outstanding

10-K filing | 26.0M shares outstanding

10-Q filing | 26.0M shares outstanding

10-Q filing | 26.0M shares outstanding

10-Q filing | 25.9M shares outstanding

10-K filing | 25.9M shares outstanding

POS AM filing: This is a POS AM filing to terminate the effectiveness of the Original Registration Statement and to deregister all the Registered Shares that remain unsold under the Original Registration Statement as of the date thereof.

POS AM filing: This is a post-effective amendment to terminate the effectiveness of the original registration statement and to deregister all the registered securities that remain unsold.

S-3 filing: This S-3 filing registers 11,392,350 shares of common stock for resale by selling stockholders, consisting of Merger Common Shares, Merger Conversion Shares, and Private Placement Conversion Shares, with the company not receiving any proceeds from the sale.

S-3 filing: Cartesian Therapeutics, Inc. files an S-3 form to offer and sell up to $400,000,000 in the aggregate of common stock, preferred stock, and debt securities.

S-3 filing: This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein of up to (i) 5,813,223 shares of our common stock, and (ii) 437,927 shares of Common Stock, issuable upon the conversion of 437,927 shares of Series B Non-Voting Convertible Preferred Stock.

10-Q filing | 25.4M shares outstanding

S-1/A filing: This S-1/A filing registers for resale up to 6,501,150 shares of common stock, including shares issuable upon conversion of Series B Preferred Stock. The selling stockholders will receive the proceeds from the sale of these shares.

S-1/A filing: This S-1/A filing relates to the resale of common stock and common stock issuable upon conversion of Series B Preferred Stock by selling stockholders.

10-Q filing | 21.4M shares outstanding

S-1 filing: This S-1 filing registers shares of common stock and shares of common stock issuable upon conversion of Series B Preferred Stock for resale by selling stockholders.

10-Q filing | 17.8M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 155,109,561 → 5,515,835

10-K filing | 155.1M shares outstanding

10-Q filing | 154.8M shares outstanding

S-3 filing: Selecta Biosciences, Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock, and debt securities, warrants and units up to an aggregate amount of $200,000,000.

10-Q filing | 153.4M shares outstanding

10-Q filing | 153.3M shares outstanding

10-K filing | 145.9M shares outstanding

10-Q filing | 152.8M shares outstanding

10-Q filing | 148.5M shares outstanding

10-Q filing | 151.8M shares outstanding

10-K filing | 114.3M shares outstanding

10-Q filing | 115.2M shares outstanding

10-Q filing | 113.5M shares outstanding

10-Q filing | 113.2M shares outstanding

10-K filing | 112.4M shares outstanding

10-Q filing | 108.0M shares outstanding

8-K filing: Selecta Biosciences, Inc. entered into a term loan facility of up to $35.0 million with Oxford Finance LLC and Silicon Valley Bank, and issued warrants to the lenders to purchase an aggregate of 203,850 shares of common stock at an exercise price of $2.54 per share.

S-3 filing: Selecta Biosciences, Inc. is offering common stock and other securities up to an aggregate amount of $200,000,000 from time to time.

10-Q filing | 86.3M shares outstanding

8-K filing: Selecta Biosciences, Inc. sold 5,416,390 shares of common stock to Swedish Orphan Biovitrum AB at a purchase price of $4.6156 per share, resulting in aggregate gross proceeds of $25 million. ($25.0M proceeds)

10-Q filing | 86.3M shares outstanding

10-K filing | 22.5M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale of up to 68,965,512 shares of common stock by selling stockholders.